MEREO BIOPHARMA GROUP PLC (MREO) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 0.00 USD | |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $0.00 | (m) | (m) |
| 2025-12-31 | (m) | $500.00K | (m) | (m) |
| 2025-09-30 | (m) | $500.00K | (m) | (m) |
| 2025-06-30 | (m) | $500.00K | (m) | (m) |
| 2024-12-31 | (m) | $0.00 | (m) | (m) |
| 2024-09-30 | (m) | $1.00M | (m) | (m) |
| 2024-06-30 | (m) | $1.00M | (m) | (m) |
| 2024-03-31 | (m) | $10.00M | (m) | (m) |
| 2023-12-31 | (m) | $10.00M | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |